Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHOC | P08134 | 9/20 | 0.52 |
| ▸ | RHOA | P61586 | 9/20 | 0.52 |
| ▸ | CSF1R | P07333 | 4/20 | 0.50 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.49 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.49 |
| ▸ | NPY2R | P49146 | 2/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.45 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1420533 | 0.93 | TRPV4 (0.57) | CSF1RTRPV4NPY2R | |
| SCHEMBL1420444 | 0.91 | CSF1R (0.47) | CSF1RTRPV4DDR1NPY2RHRH3 | |
| SCHEMBL1420438 | 0.90 | CYP3A4 (0.54) | CSF1RTRPV4DDR1NPY2R | |
| SCHEMBL1420117 | 0.90 | LMNA (0.49) | CSF1RTRPV4NPY2R | |
| SCHEMBL1420605 | 0.89 | NPY2R (0.51) | RHOCRHOACSF1RDDR1NPY2R | |
| SCHEMBL1961881 | 0.89 | CSF1R (0.47) | CSF1RTRPV4DDR1NPY2R | |
| SCHEMBL1420252 | 0.89 | CSF1R (0.47) | CSF1RTRPV4DDR1NPY2R | |
| SCHEMBL1420411 | 0.89 | NPY2R (0.52) | RHOCRHOACSF1RDDR1NPY2R | |
| SCHEMBL1420327 | 0.88 | TRPV4 (0.48) | CSF1RTRPV4NPY2R | |
| SCHEMBL1420492 | 0.88 | CSF1R (0.54) | CSF1RTRPV4DDR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011524365-A | — | — | 2011-09-01 | — | — | JP | claimed |
| US-20110144107-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA | IRM LLC (BM) | 2011-06-16 | — | — | US | claimed |
| EP-2297097-A2 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA | IRM LLC (BM) | 2011-03-23 | — | — | EP | claimed |
| WO-2009152356-A2 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA | IRM LLC (BM) | 2009-12-17 | — | — | WO | claimed |
| US-20110144107-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA | IRM LLC (BM) | 2011-06-16 | — | — | US | disclosed |
| US-20110144107-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA | IRM LLC (BM) | 2011-06-16 | — | — | US | disclosed |
| EP-2297097-A2 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA | IRM LLC (BM) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009152356-A2 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA | IRM LLC (BM) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144107-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA | G6PD, DHFR, SGMS1 | RHOC 595/4885RHOA 451/4885CSF1R 2076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.